ClinicalTrials.gg
RecruitingNCT06414265CASSINI-EUUpdated May 20, 2026

Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation

An interventional study of Transcatheter mitral valve replacement in Heart Failure, sponsored by InnovHeart. Recruiting at 8 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by InnovHeart · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Heart Failure with a site in Georgia — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure · Georgia.

Planned enrollment
29th of 44
30 · median 50
Started
2024
with 5 others
No phase
25 of 46
15 open now
Primary completion
2027-03
later than 10 of 19 live
Registered
39th of 46
by date

Among the 46 studies in Heart Failure with a site in Georgia, this one is the 29th largest by planned enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2024, is one of 25 with no phase, reaches primary completion later than 10 of the 19 other live ones, and was the 39th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

18 of the 46 studies in Heart Failure with a site in Georgia are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Heart Failure with a site in Georgia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate feasibility, safety, and performance of the SATURN TS TMVR System for the treatment of moderate-to-severe or severe, symptomatic mitral regurgitation through a transcatheter approach. The main questions it aims to answer are:

  • is the use of the device feasible?
  • is it safe (defined as freedom from device-related major adverse events at 30 days)?
  • does it perform (defined as reduction of MR Grade to ≤ 1+ at 30 days)?

Participants will need to do the following as part of the clinical trial:

  • complete 6-Minute Walking Test
  • complete Quality of Life Questionnaires
  • undergo blood evaluations
  • CT scan
  • 12 lead ECG
  • Transesophageal Echocardiography
  • Transthoracic Echocardiogram
  • the study procedure (valve implantation, right heart catheterization, left arterial pressure, fluoroscopy/ angiogram)
Read the detailed description

The SATURN Trans-Septal Transcatheter Mitral Valve Replacement System (SATURN TS System) is intended for use in adult patients suffering from heart failure symptoms (NYHA class II or greater) with moderate to severe or severe mitral regurgitation (MR ≥3+) who are deemed to be at high risk for open-heart mitral valve surgery by a multidisciplinary Heart Team including at least a cardiac surgeon and a cardiologist, experienced in the care of patients with mitral valve disease.

CASSINI-EU is a single-arm, prospective, multicenter pilot trial. The purpose of the study is to evaluate feasibility, safety, and performance of the SATURN TS TMVR System for the treatment of moderate-to-severe or severe, symptomatic mitral regurgitation through a transcatheter approach.

Primary objectives are to evaluate the feasibility, safety and performance of the SATURN TS TMVR System at 30 days. Secondary objectives and additional outcomes are long term safety and performance of the SATURN TS TMVR System.

Up to 30 patients will be treated at up to 6 qualified investigational sites in Europe.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 65 years or older.
  2. Symptomatic moderate to severe or severe functional mitral regurgitation (≥ Grade 3+).
  3. functional Class ≥ II. If Class IV, patient must be ambulatory.
  4. Ability to tolerate oral anticoagulation.
  5. Ability to qualify for bailout surgery (which may include open heart surgery).
  6. High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team.
  7. Willing and able to complete study-related assessments and questionnaires.

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria

  1. Degenerative (i.e. intrinsic valve lesions) mitral regurgitation.
  2. Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement.
  3. \<1 year due to noncardiac conditions.
  4. Endocarditis in the 3 months prior to procedure date.
  5. Current admission with acute heart failure exacerbation.
  6. Dependency on inotropic agents or mechanical circulatory support.
  7. Untreated CAD.
  8. Active systemic infection.
  9. Modified Rankin Scale ≥4 disability.
  10. Chronic renal failure defined as \<30 mL/min/m2 or on renal replacement therapy.
  11. Severe pulmonary arterial hypertension (PAH), defined as PASP > 60mmHg.
  12. \< 90,000.
  13. 2 on home oxygen therapy deemed too high risk for intubation.
  14. Refuses blood transfusions.
  15. Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states).
  16. Severe connective tissue disease under chronic or cortisone therapy.
  17. Participating in other studies likely to confound the results or affect the study.
  18. Unable or does not sign the study form.
  19. Patients classified as "vulnerable patients" 3 .

    Cardiovascular Exclusion Criteria

  20. Myocardial infarction during prior 30 days.
  21. Stroke or during prior 90 days.
  22. Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed).
  23. Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment.
  24. Prior surgical mechanical valve AVR.
  25. Prior TAVI.
  26. Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure.
  27. CRT or ICD implanted in previous 30 days.
  28. Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure \<90mmHg, Inotropic dependent or requiring IABP/mechanical circulatory support.
  29. CABG or PCI within previous 30 days.
  30. Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee.
  31. Prior or planned heart transplantation (UNOS status 1).
  32. Physical evidence of right-sided congestive heart failure:

    1. Patients with ascites.
    2. Patients with anasarca (generalized edema / hydropsy).
  33. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy.

    Procedural Exclusion Criteria

  34. Known or to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy).
  35. Documented hypersensitivity to nickel or titanium.
  36. Contraindications to TEE imaging

    Cardiac Imaging Exclusion Criteria

  37. Left ventricular EF ≤ 30% by echocardiogram.
  38. Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass.
  39. Extensive mitral flail leaflets
  40. Evidence of new or untreated intracardiac thrombus, mass, or vegetation.
  41. Severe right ventricular dysfunction.
  42. Severe tricuspid regurgitation.
  43. Hemodynamically significant inter-atrial shunt (ASD).
  44. Severe aortic regurgitation or aortic stenosis.
  45. Anatomic ineligibility for SATURN TS Bioprosthetic System or SATURN TS procedure as determined by the Screening Committee.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    SATURN Trans-septal Transcatheter mitral valve replacement (TMVR) System

    Device: Transcatheter mitral valve replacement

Interventions

  • DeviceTranscatheter mitral valve replacement

    The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.

06

What researchers measure

Primary outcomes

  1. Safety Endpoint - Freedom from Device Related Major Adverse Events

    Freedom from device-related major adverse events

    Time frame: 30 days post-procedure

  2. Technical Procedural Success Endpoint

    Technical success defined as alive patient at exit from procedure room with all the following: * Successful access, delivery of the SATURN TS Bioprosthesis, and retrieval of the TS Delivery Systems * Correct positioning of the first intended SATURN TS Bioprosthesis * Freedom from emergency surgery or mitral valve re-intervention related to the device or access procedure

    Time frame: Procedure

  3. Efficacy Endpoint - Reduction of Mitral Regurgitation Grade to ≤ 1+

    Reduction of MR Grade to ≤ 1+

    Time frame: 30 days post-procedure

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2027, 35 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 35 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 16, 2024
StartActual
Apr 4, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Feb 2030
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06414265
Lead sponsor
InnovHeart
Collaborators
Avania
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Apr 4, 2024
Primary completion
Mar 2027 (estimated)
Completion
Feb 2030 (estimated)
Last update
May 20, 2026

Study contacts

VP, Clinical Affairs InnovHeart
Contact
a.roach@innovheart.com
+49 69 24003626
Maxis Operations
Contact
maxisoperations@maxismedical.com
Paolo Denti, MD
principal investigator · San Raffaele Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion